Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Cell Environment


64 rue Guy Moquet
94500 Champigny sur Marne – France

Contact : radhia.mkacher@cell-environment.com

Radhia M’kacher : Présidente directrice générale
Web Site >
Cell Environment - Genopole's company Cell Environment - Genopole's company

Booster#Health / Well-being #Diagnostics

  • DNA damage
  • Repeated sequences
  • Unique sequences
  • Telomeres
  • Centromeres

Field of Activity


Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.

BACKGROUND

Our academic research developed over 20 years reliable, sensitive and automated methods to detect DNA damage. Cell Environment was created to transfer these techniques into the clinics.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

Cell Environment developed a high throughput genomic cytogenetic approach based on a very small amount of samples. This process associates telomere quantification to the analysis of chromosomal aberrations and the detection of chromosomal instability.

This approach is a break with the existent techniques. In order to transfer this approach in the clinics, we developed the kits of telomere and centromere staining as well as the software for automated analysis.

ACCOMPLISHMENTS / COLLABORATIONS / HIGHLIGHTS

The first flagship products resulting from this innovation are

  1. telomere and centromere staining kits.
  2. development of three analysis software
  3. creation of an automated analysis platform.

A validation of the approach was performed against clinical cytogenetics. A patent has been filed. The company has been approved as an R&D provider since 2017.

COLLABORATIONS SOUGHT

Cell Environment has started the industrialization and commercialization phase and we are looking for partners for the distribution of kits and funds to make our solution more relevant.

  • Futher informations

    1 Patent

    Les forces :
    Automation of the detection of DNA damage involving unique and repeated sequences.
    Scientific soundness (more than 14 scientific publications) and collaborative networks.

    Le + innovation :
    The use of a small amount of samples.

Share
Genopole’s Companies

#Diagnostic


In same field

Logo Integragen - Genopole's Company

Integragen

IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.

Discover
logo GenoSplice - Genopole's Company

GenoSplice

Bioinformatics service provider (gene expression, splicing, SNP, CNV, epigenetics, data integration).

Discover
Endodiag - Genopole's company

Endodiag

Design, development and commercialization of medical devices and services for the diagnosis of endometriosis.

Discover
Enalees - Genopole's company

Enalees

Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.

Discover
AgenT Biotech - entreprise génopolitaine

AgenT

AgenT is developing an unprecedented blood test to identify patients with Alzheimer's disease much earlier in disease course than current detection methods are able to do. The company also does drug repositioning research to identify compounds potentially active in the silent phase of Alzheimer's disease.

Discover
View all >
With support